Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

Not Applicable

Completed

• Conditions: Chemotherapy Induced Nausea and Vomiting

• Registration Number: NCT00211601
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-08
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-21
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-30
• Last Update Posted: 2015-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion Criteria

• Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
CINV at the delayed phase during cycle 2

Secondary Outcome Measures

Name	Time	Method
Treatment for CINV